SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation F11N

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 2 clinical trials

Clinical Trials


1 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.

The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on more than 90 % of medullary thyroid carcinomas. In the pilot (phase 0) study investigators will correlate the tumour detection rate with the surgery and histology (proof of concept study). Furthermore, kidney protection and dosimetry studies will be performed in order to determine the kidney protection protocol and starting activity for the dose escalation study in the following, dose escalation (phase I) study. In the phase I study investigators will determinate the maximum tolerated dose of 177Lu-PP-F11N in patients with MTC. Furthermore, correlation with tumour radiation dose and treatment response as well as organ radiation doses and maximal tolerated dose will be performed in order to allow prospective individual patient tailored therapy planning.

NCT02088645 Thyroid Cancer, Medullary Drug: 177Lu-PP-F11N
MeSH:Thyroid Neoplasms Thyroid Diseases
HPO:Abnormality of the thyroid gland Neoplasm of the thyroid gland Thyroid adenoma Thyroid carcinoma Thyroid follicular adenoma

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.. 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. --- F11N ---

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.. 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. --- F11N --- --- F11N ---

The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). --- F11N ---

177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors. --- F11N ---

In the phase I study investigators will determinate the maximum tolerated dose of 177Lu-PP-F11N in patients with MTC. --- F11N ---

Phase 0 study: Evaluation of the scintigraphic visualisation of metastases after test injection, verification of 177Lu-PP-F11N uptake in metastases and correlation with surgery/histology if possible (poof of principle study).. Phase I: Maximum tolerated dose. --- F11N ---

Evaluation of in vivo stability of 177Lu-PP-F11N.. Phase 0: Metabolites. --- F11N ---

Measurement of the metabolites of 177Lu-PP-F11N with and without Physiogel infusion.. Phase I: Side reactions. --- F11N ---

Evaluation of side reactions of 177Lu-PP-F11N.. Phase 1: Biochemical response. --- F11N ---

Evaluation of in vivo stability of 177Lu-PP-F11N.. Phase 1: Metabolites. --- F11N ---

Measurement of the metabolites of 177Lu-PP-F11N.. Inclusion Criteria: Phase 0 study - Advanced MTC with elevated levels of calcitonin (> 100 pg/ml) and/or calcitonin-doubling time < 24 months before or after total thyroidectomy - Age > 18 years - Informed consent Phase I study - Diagnostic, contrast medium enhanced CT scan neck/thorax/abdomen, not older than 4 weeks - Advanced MTC with elevated levels of calcitonin (> 100 pg/ml) and/or calcitonin-doubling time < 24 months before or after total thyroidectomy- Age > 18 Years - Informed consent - Curative surgical therapy not possible Exclusion Criteria: Phase 0 study - Medication with Vandetanib 3 weeks before the study and during the study - Renal failure (calculated glomerular filtration rate (GFR) < 60 ml/min per 1.73 m2 body surface). --- F11N ---

Primary Outcomes

Description: Phase 0 study: Evaluation of the scintigraphic visualisation of metastases after test injection, verification of 177Lu-PP-F11N uptake in metastases and correlation with surgery/histology if possible (poof of principle study).

Measure: Phase 0: Scintigraphic visualisation rate

Time: up to 4 weeks

Description: Phase I study: Determination of the maximum tolerated dose (MTD)

Measure: Phase I: Maximum tolerated dose

Time: Up to 9 months

Secondary Outcomes

Description: Evaluation of the kidney radiation dose and the tumour-to-kidney radiation dose ratios with and without kidney protection (Physiogel). Composite measure.

Measure: Phase 0: Tumour-to-kidney radiation doses

Time: 8 and 16 weeks

Description: Calculation of tumour and organ radiation doses.

Measure: Phase 0: Radiation doses

Time: 8 and 16 weeks

Description: Evaluation of in vivo stability of 177Lu-PP-F11N.

Measure: Phase 0: In vivo stability

Time: 8 and 16 weeks

Description: Measurement of the metabolites of 177Lu-PP-F11N with and without Physiogel infusion.

Measure: Phase 0: Metabolites

Time: 8 and 16 weeks

Description: Evaluation of side reactions of 177Lu-PP-F11N.

Measure: Phase I: Side reactions

Time: 8, 16 and 24 weeks

Description: Evaluation of biochemical response (decrease of calcitonin and calculation of calcitonin doubling time).

Measure: Phase 1: Biochemical response

Time: For the duration of 24 months.

Description: Evaluation of morphological therapy response (RECIST criteria).

Measure: Phase I: Morphological response

Time: 0, 3 and 12 months

Description: Determination of the tumour detection rate and correlation with surgery/histology, if possible.

Measure: Phase I: Tumour detection rate

Time: 8, 16 and 24 weeks

Description: Calculation of organ radiation doses after therapy and correlation with the determined MTD (composite measure).

Measure: Phase I: Organ radiation doses

Time: 8, 16 and 24 weeks

Description: Determination of overall survival of patients after therapy.

Measure: Phase 1: Overall survival

Time: Up to 5 years

Description: Evaluation of in vivo stability of 177Lu-PP-F11N.

Measure: Phase 1: In vivo stability

Time: 8, 16 und 24 weeks

Description: Measurement of the metabolites of 177Lu-PP-F11N.

Measure: Phase 1: Metabolites

Time: 8, 16 and 24 weeks

2 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed Phase 0/B)

The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on more than 90 % of medullary thyroid carcinomas.

NCT03647657 Thyroid Cancer, Medullary Drug: 177Lu-PP-F11N Drug: Sacuitril
MeSH:Thyroid Neoplasms Thyroid Diseases
HPO:Abnormality of the thyroid gland Neoplasm of the thyroid gland Thyroid adenoma Thyroid carcinoma Thyroid follicular adenoma

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed Phase 0/B). --- F11N ---

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). --- F11N ---

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). --- F11N --- --- F11N ---

177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors. --- F11N ---

Evaluation of the radiation doses in tumor tissue from MTC after injection of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto). --- F11N ---

Evaluation of the radiation doses in the kidneys and the tumor-to-kidney dose ratios after injection of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto). --- F11N ---

Evaluation of the radiation doses in other organs and the appropriate organ-to-kidney dose ratios after injection of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto). --- F11N ---

Measurement (HPLC) of the in-vivo stability of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto).. Autoradiography. --- F11N ---

Comparison of tumor imaging by 68Ga-DOTATOC PET/CT and 177Lu-PP-F11N SPECT/CT. --- F11N ---

- Pregnancy and breast feeding - Known, serious side reaction in the case of a former application of pentagastrin - Active, second malignancy oder remission after second malignancy < 5 years - Age over 64 years - Systolic bood pressure < 112 mmHg at the time of screening - Simultaneous medication with angiotensin converting enzyme (ACE)-inhibitors, or withdrawal for less than 36 h prior to the medication with Entresto or simultaneous medication with AT-II-receptor blockers - Known intolerance to Sacubitril or Valsartan - Known angioedema in anamnesis in the context of a medication with an ACE-inhibitor or an AT-II-receptor blocker Thyroid Cancer, Medullary Thyroid Neoplasms Thyroid Diseases A phase 0 study (Lumed study part A) was already performed, showing low toxicity of 177Lu-PP-F11N and tumor uptake in all patients. --- F11N ---

Co-injection of Physiogel (Gelofusin) showed insignificant reduction of kidney uptake and can therefore be omitted for a radionuclide therapy with 177Lu-PP-F11N. --- F11N ---

In this study, the effect of the NEP-1 inhibitor Sacuitril on the in-vivo stability of 177Lu-PP-F11N and the uptake, respectively radiation doses in MTC metastases and organs will be evaluated, using a cross-over design already used for the Lumed part A study. --- F11N ---

Each patient will receive two injections of 177Lu-PP-F11N, with and without additional medication with Sacuitril Imaging findings, acquired by SPECT/CT, will be compared to imaging with 68Ga-DOTATOC positron emission tomography (PET)/CT. --- F11N ---

Primary Outcomes

Description: Evaluation of the radiation doses in tumor tissue from MTC after injection of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto)

Measure: Tumor radiation doses

Time: Measurement up to 72 hours after each injection of 177Lu-PP-F11N

Secondary Outcomes

Description: Evaluation of the radiation doses in the kidneys and the tumor-to-kidney dose ratios after injection of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto)

Measure: Kidney radiation doses

Time: Measurement up to 72 hours after each injection of 177Lu-PP-F11N

Description: Evaluation of the radiation doses in other organs and the appropriate organ-to-kidney dose ratios after injection of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto)

Measure: Organ radiation doses

Time: Measurement up to 72 hours after each injection of 177Lu-PP-F11N

Description: Measurement (HPLC) of the in-vivo stability of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto).

Measure: In-vivo stability

Time: Blood samples for measurement 5 and 30 minutes post injection of 177Lu-PP-F11N

Description: In case of surgery with available tumor tissue samples, imaging results will be compared with autoradiographic analysis of somatostatine- and CCK2-receptor expression in tumor tissue.

Measure: Autoradiography

Time: Through study completion, up to 18 months

Other Outcomes

Description: Chromogranine A blood values will be compared to the radiation doses of the stomach.

Measure: Chromogranine A

Time: Measurement up to 72 hours after the first injection of 177Lu-PP-F11N

Description: Comparison of tumor imaging by 68Ga-DOTATOC PET/CT and 177Lu-PP-F11N SPECT/CT

Measure: 68Ga-DOTATOC PET/CT

Time: Measurement up to 72 hours after each injection of 177Lu-PP-F11N


HPO Nodes


HP:0000820: Abnormality of the thyroid gland
Genes 475
SRD5A3 IYD IL2RG GABRA3 ATRX PAX8 IDH2 DMXL2 DUOX2 TNFSF15 GATA1 TCF4 KCNJ10 TWNK RRM2B TTC37 DCLRE1C MC2R ALX4 EXT2 PLCG2 SDHD XRCC4 GABRD FASLG TRNL1 BCL10 BUB1 NKX2-1 TSHR CHD7 FOXP3 FMR1 TSHB LHX4 SETBP1 PDE4D MST1 MALT1 MSTO1 SLC26A4 AIP CDH23 RPS20 GLIS3 BMPR1A SUFU TRNN GNAS TRNL2 PDE4D SUFU FOXP1 TBX1 PIEZO1 ND1 NRAS HBB CLCNKB COX2 EDN3 ZFAT EYA1 GCH1 EIF2AK3 EFEMP2 GLI2 TRAPPC9 PTEN PAX8 SEMA4A HABP2 UFD1 FGF8 PAX8 RNASEH2A LRBA TDGF1 B3GLCT FOXE1 LHX3 TG RET RMRP HRAS TSHR CTNS CASR NKX2-1 TRNQ HSD17B3 EDNRB CDKN2B JMJD1C SGPL1 NKX2-1 PROP1 IFNG THRB FLCN SLC5A5 THRB MLH1 POLG TSHR KCNJ18 KDM6A FUT8 CDKN1A CCBE1 IL12A LIG4 HLA-DRB1 FBLN5 TRNS1 ALMS1 DCLRE1C FOXE1 MSH3 TMEM67 CTNNB1 PAX8 TG POLG2 SEC24C SEMA3E SDHC ZIC2 TNPO3 SLC25A4 LEPR TSHR MMP2 USP9X FOXE1 LEP BIRC3 SDHB WDR4 GDNF LMNA CDKN1B LHX3 TRNL1 TBCK NNT THRA FOXI1 NNT COMT ACP5 POU1F1 SOX3 STAT1 PROKR2 GNAS VPS13A SEMA3D SOX3 TGFBR2 APC LIFR MINPP1 DISP1 CTNS THRB PROP1 SUGCT WDR11 DDOST COX1 TSHR ELN TBX1 PTEN LIG4 TXNRD2 ND5 SIX3 RAG1 ND4 TREX1 SEC23B TSHB CDKN1B RAI1 ADAT3 ELN TPO CEP57 USF3 FOXA2 RREB1 BUB3 SRY IGSF1 PDGFB CDC73 DUOXA2 DEAF1 BCOR FOXI1 PROP1 KLLN HSD17B3 KAT6B FOXP3 NSDHL DLL1 MMP14 WRN GP1BB GLI3 CEP57 BMP4 RFC2 NRTN SRGAP1 CACNA1S KISS1R PPP1R15B STAT3 ND6 CDKN2C TSHR TANGO2 HESX1 RET GPC1 STUB1 HNF1B AKT1 DICER1 TRNF NODAL SLC26A4 DNAJC19 PMM2 DICER1 CTLA4 PRDM16 ITCH GLI2 GNE SKI POLR1D KCNAB2 INSR SLC12A3 ENPP1 WFS1 GLI3 LIMK1 MRAP PTEN TBL2 RNASEH2B TWNK TGIF1 NKX2-5 ZBTB20 POMC TSHR PTEN YY1 DNM1L RERE NKX2-5 MARS1 SCN4A MSH3 ABCC6 IL7R GATA6 GREM1 PRKAR1A ADAMTSL1 POU3F4 EXOSC2 SLC6A17 LEPR KEAP1 CHD7 FUCA1 WFS1 APC IFIH1 HIRA RAI1 AFF4 PIK3C2A RBM28 FGFR1 ARNT2 KMT2D POU2AF1 SMARCB1 CLIP2 SEC23B CACNA1S ALG8 CP MEN1 TPO PPP1R15B PLVAP FAS SIX1 GNAS FANCI BUB1B RET DACT1 HABP2 C1QBP PTRH2 ADAR GAS1 ADA STAT1 SHH STAR IL12RB1 IRF5 FOXH1 TBC1D24 BMPR1A MINPP1 TRHR NKX2-5 POLR1C TRH DNAH1 PMS1 NKX2-1 PIK3CA RAG2 PCSK1 FDX2 GNAS FOXE1 MSTO1 RAI1 MSH6 TF TBX2 FLII FOXE1 TONSL APC STEAP3 BRAF PIK3CA SKIV2L TG HPD POLG LHX4 PROP1 PIK3CA EPCAM FOXD3 TRNS1 KCNJ18 MEN1 IQSEC2 SAA1 KRAS SLC5A5 KAT6B DUOX2 TRIP13 UBR1 SLC26A4 TSC2 IGH AKT1 USP9X ALMS1 PMS2 RCBTB1 APC HBB RASGRP1 CASP10 ROBO1 POU1F1 NPHS1 DMXL2 CDC73 ARVCF GTF2I DUOXA2 TRNW COX3 LHX4 POLR3A PLAA IL2RA CDON PRKAR1A HNF4A RNASEH2C JAG1 BTNL2 TRNH OPA1 DICER1 KIAA0556 NLRP1 TCOF1 APOE GPR35 TBX1 SLC16A2 PRKCD AIRE KCNJ10 HESX1 TRNS2 MLXIPL SAMHD1 TRMT10A LIG4 SEMA3C FMR1 CDH23 TANGO2 TSHR FLCN PTCH1 HESX1 BAZ1B FAN1 CDC73 POU1F1 GPR161 C1S IYD PHF21A MEN1 IDH1 LRP4 DUOX2 RET APC CACNA1C SASH1 PTEN TTC7A OTX2 MSH2 ECE1 APC TRNW MMEL1 SALL1 MCM8 XRCC4 DCAF17 FAS MLH3 SALL1 FOXP1 SPIB NF2 CLPB CDON LHX4 NIN ARL6IP6 GTF2IRD1 SLC26A4 TSC1 PRKAR1A
Protein Mutations 4
F11N K601E V600E V600K
SNP 0